News

Extending antimicrobial stewardship programs to transition of care and discharge may prove beneficial to reduce unnecessary antibiotic use.

That country is trying to contain the virus to prevent further cases, as well as other African countries met to try to prevent an outbreak inside their own borders.

Before the emergence of COVID-19, this precursor virus was a global concern.

Over the past decade, the number of cases of hepatitis A infection at a Turkish hospital has decreased, but a growing proportion of cases come from migrants to the country.

CRISPR edit of proviral DNA tested as potential cure for HIV in first participant of phase 1/2 clinical trial.

Articles covering respiratory infections were our most-clicked this week.

Moderna’s new bivalent COVID-19 booster, which includes 25 micrograms each of messenger RNAs from the Wuhan-Hu-1 and Omicron B.1.1.529 variants of SARS-CoV-2, elicited antibody responses that were superior to those elicited by the original vaccine.

Hepatitis A infections occurred almost exclusively among adults in states with outbreaks.

Preliminary results from a phase 2/3 trial suggest Pfizer-BioNTech’s Omicron BA.4/BA.5 bivalent COVID-19 booster vaccine provides better protection for younger and older adults.

The Moderna vaccine can be administered to children as young as six years old and the Pfizer-BioNTech vaccine for kids as young as five years old.

Pediatric populations are disproportionately affected by influenza. The first cell-based quadrivalent flu vaccine offers potential for greater vaccine effectiveness.

A comprehensive cohort study of COVID-19 data has reinforced the effectiveness of the various vaccines, boosters, and prior infection in protecting against infection, hospitalization and death.

Novel β-lactamase inhibitor enmetazobactam with cefepime exceeded noninferiority to piperacillin/tazobactam in complicated UTI, pyelonephritis.

A recent study broke down hospitalizations associated with COVID-19 in adults between January 2021 and April of this year, based upon vaccination status.

The vaccine is meant to be administered during the third trimester of pregnancy to the expecting mother to prevent this respiratory disease in infants younger than 2 months of age.

These were our most popular articles this week. Catch up with these trending infectious disease stories.

“Too few persons are receiving timely treatment” with direct-acting antiviral for hepatitis C based on their first positive test result, the study authors wrote.

The FDA cleared zetomipzomib as an Investigational New Drug. A phase 2 clinical trial is the next step for this autoimmune hepatitis treatment.

The intervention included meeting with experts, texting services to improve and facilitate communication, and data collection and dissemination.

The federal agency said it was looking at a multistate outbreak of the infection connected to Brie and Camembert soft cheese products manufactured by Old Europe Cheese.

Oral antibiotics after partial completion of intravenous regimen for S aureus bacteremia improves outcomes of persons who inject drugs (PWID), which is a population that often has limited access to treatment.

The CDC is urging all eligible persons to receive a flu shot, but a new survey shows fewer adults are planning to get the vaccine this season.

Bulevirtide, a first-in-class entry inhibitor, showed promise for the treatment of hepatitis B and hepatitis D coinfection, a phase 2 trial found.

Yasaswi Kislovskiy, MD, MSc, specialized in reproductive infectious disease to advocate for gender equity in health care.

Experts are advocating for occult hepatitis B to be spotlighted.

With proper treatment, even the youngest sufferers can recover. Know the signs when treating potentially infected children, especially if they have environmental risk factors.

Largest extended study of outcomes after rare myocarditis from mRNA COVID-19 vaccines finds most recover and regain quality of life.

Catch up on Contagion's top stories from the month of September.